Please use this identifier to cite or link to this item: doi:10.22028/D291-41466
Title: Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker
Author(s): Burgard, Caroline
Engler, Jakob
Blickle, Arne
Bartholomä, Mark
Maus, Stephan
Schaefer-Schuler, Andrea
Khreish, Fadi
Ezziddin, Samer
Rosar, Florian
Language: English
Title: Frontiers in Medicine
Volume: 10
Publisher/Platform: Frontiers
Year of Publication: 2024
Free key words: PSMA—prostate-specific membrane antigen
radioligand therapy
prostate cancer
dual imaging
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Purpose: The value of [18F]fluorodeoxyglucose ([18F]FDG) PET/CT in monitoring prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) is still unclear. The aim of this study was to identify appropriate prognostic dynamic parameters derived from baseline and follow-up [18F]FDG and dual [18F] FDG/[68Ga]Ga-PSMA-11 PET/CT for monitoring early non-responding mCRPC patients undergoing PSMA-RLT. Methods: Twenty-three mCRPC patients of a prospective registry (NCT04833517), who were treated with [177Lu]Lu-PSMA-617 RLT and classified as early non-responders were included in this study. All patients received dual PET/ CT imaging with [18F]FDG and [68Ga]Ga-PSMA-11 at baseline and after median two cycles of RLT. We tested potential biomarkers representing the “change of glucometabolic activity (cGA)” and “change of glucometabolic activity in relation to PSMA expression (cGAP)” composed of established parameters on [ 18F]FDG PET/CT as SUVmax, cumulative SUV of five lesions (SUV5), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) and its corresponding parameters on [68Ga]Ga-PSMA-11 PET/CT, respectively, for association with overall survival (OS). Results: Kaplan–Meier analyses showed no significant association with OS for each tested cGA (cGASUVmax p =  0.904, cGASUV5, p =  0.747 cGAMTV p =  0.682 and cGATLG p =  0.700), likewise the dual imaging biomarkers cGAPSUVmax (p =  0.136), cGAPSUV5 (p =  0.097), and cGAPTV (p =  0.113) failed significance. In contrast, cGAPTL, which is based on TLG and total lesion PSMA (TLP) showed a significant association with OS (p =  0.004). Low cGAPTL (cut-off 0.7) was associated with significant longer survival (17.6 vs. 12.9  months). Conclusion: The novel biomarker cGAPTL, which represents the temporal change of whole-body TLG normalized by TLP, predicts overall survival in the challenging cohort of patients non-responding to PSMA-RLT.
DOI of the first publication: 10.3389/fmed.2023.1339160
URL of the first publication:
Link to this record: urn:nbn:de:bsz:291--ds-414663
ISSN: 2296-858X
Date of registration: 22-Jan-2024
Description of the related object: Supplementary material
Related object:
Faculty: M - Medizinische Fakultät
Department: M - Radiologie
Professorship: M - Prof. Dr. Samer Ezziddin
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
fmed-10-1339160.pdf1,64 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons